Several BMDCs have been identified in the tumor microenvironment such as tumor-associated macrophages (TAMs), pro-angiogenic monocytic cells, myeloid cells, and Tie-2-expressing macrophages (Lord and Harris, 2010)
The injectable GLP-1 RAs liraglutide 3 mg once daily and semaglutide 2.4 mg once weekly have both gained a licence for weight loss, alongside lifestyle management, in obese/overweight people without T2D (SmPC, 2023b
The activation of GLP-1 receptors results in: Increased insulin release in response to meals Decreased glucagon secretionwhich typically raises blood sugar levels Delayed gastric emptying This combination leads to heightened feelings of fullness and reduced food intake
Verifying purity through independent testing labs and choosing reputable peptide vendors becomes even more important for sublingual formulations, where compounding quality directly affects absorption
The differences are the approved indications (diabetes mellitus vs weight loss) and route of administration (subcutaneous injection vs oral)
